Myasthenia Gravis : Current Review  

Oleh:

Pinzon, Rizaldy

Jenis: Article from Journal - ilmiah nasional - tidak terakreditasi DIKTI
Dalam koleksi: Cermin Dunia Kedokteran vol. 36 no. 06/172 (Sep. 2009), page 413.
Topik: myasthenia; immunology fi diagnosis fi treatment; prognosis

Ketersediaan

Perpustakaan FK Nomor Panggil: C04.K.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

myasthenia gravis (MG) is an acquired autoimmune disorder characterized clinically by weakness of skeletal muscles and fatigability on exercise. Weakness increases during the day and improves with rest. Extraocular muscle (EOM) weakness or ptosis is present initially in 50% of patients and 90% occurs during the course of illness. AChE inhibitors and immunomodulating therapies are the mainstays of treatment. In mild form, AChE inhibitors are used. Important risk factors for poor prognosis include age older than 40 Years, A progressive disease, and thymoma.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali